literature

HBV mutation literature information.

Analysis of HBV genotype, drug resistant mutations, and pre-core/basal core promoter mutations in Korean patients with acute hepatitis B.

PMID: 25712861 2015 Journal of medical virology

Abstract: No patient showed mutations that conferred resistance against lamivudine (L180M, M204V/I), adefovir (A181T, N236S), or entecavir (I169M, A184T/V, S202I/G, M250V/I/L).

New amino acid changes in drug resistance sites and HBsAg in hepatitis B virus genotype H.

PMID: 25732900 2015 Journal of medical virology

Abstract: Classical lamivudine resistance mutations (rtM204V/rtL180M) were present in one naive-treatment patient infected with genotype G.

Characterization of novel entecavir resistance mutations.

PMID: 25817219 2015 Journal of hepatology

Abstract: RESULTS: RtI163V and rtA186T mutations were detected together with LAMr (rtL180M and rtM204V) at VBT.

Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Cote d'Ivoire.

PMID: 25852125 2015 Antiviral therapy

Abstract: Among 11/127 (8.7%) patients with high-level persistent viraemia (last HBV VL: >=10(5) copies/ml), only two harboured incident LAM-resistance mutations at positions rtV173L+rtL180M+rtM204V with no patient exhibiting TDF/FTC-resistance.

[The drug resistance mutation detection and relevant factors analysis of HBV P region in chronic hepatitis B patients in Weifang City, Shandong Province].

PMID: 25997324 2015 Bing du xue bao

Abstract: M204V/I mutation mostly existed in the form of joint L180M mutation, the mutation rate was age-related.

Delayed Reduction of Hepatitis B Viral Load and Dynamics of Adefovir-Resistant Variants during Adefovir plus Entecavir Combination Rescue Therapy.

PMID: 26005376 2015 International journal of medical sciences

Result: During 27-36 months of combination treatment, no LAM-resistant variants (rtM204I/V with or without rtL180M) or ETV-resistant variants (rtT184, rtS202, or rtM250) were detected in the viral population.

4'-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus.

PMID: 26122273 2015 Hepatology (Baltimore, Md.)

Abstract: Once-daily peroral administration of CAdA reduced HBVETV-RL180M/S202G/M204V viremia (P = 0.0005) in human-liver-chimeric/ HBVETV-RL180M/S202G/M204V-infected mice, whereas ETV completely failed to reduce HBVETV-RL180M/S202G/M204V viremia.

Abstract: Southern analysis using Huh-7 cells transfected with HBV-containing plasmids demonstrated that CAdA was potent against both wild-type (IC50= 7.2 nM) and ETV-resistant HBV (IC50= 69.6 nM for HBVETV-RL180M/S202G/M204V), whereas ETV failed to reduce HBVETV-RL180M/

Inhibitory effect of Phyllanthus urinaria L. extract on the replication of lamivudine-resistant hepatitis B virus in vitro.

PMID: 26220282 2015 BMC complementary and alternative medicine

Result: indicating that an additional L180M mutation in the P gene might confer LMV resistance.

Detection and analysis of resistance mutations of hepatitis B virus.

PMID: 26309637 2015 International journal of clinical and experimental medicine

Abstract: L180M, M204I and M204V were associated with the resistance to lamivudine and telbivudine; L180M, M204I, M204V and V173L were associated with the resistance to entecavir; A181T, N236T and N/H238T were related to the resistance to adefovir.

Abstract: Of multi-base mutations, L180M combined M204V had a high prevalence and were frequently found in patients with resistance to lamivudine and telbivudine.

Abstract: Of single base mutation, L180M, M204I, M

Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance.

PMID: 26322642 2015 PloS one

Introduction: The well-characterized compensatory mutations include rtL180M, rtL80I/V, and rtV173L; they enhance replication of the rtM204I/V mutants.

Introduction: They include rtI169T

Table: L180M

Browser Board

Co-occurred Entities

Filtrator